Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGDS | O60760 | 1/20 | 0.60 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.58 |
| ▸ | ATP4A | P20648 | 3/20 | 0.56 |
| ▸ | ATP4B | P51164 | 3/20 | 0.56 |
| ▸ | VCP | P55072 | 1/20 | 0.55 |
| ▸ | EIF4E | P06730 | 2/20 | 0.51 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.47 |
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | RECQL | P46063 | 1/20 | 0.46 |
| ▸ | C1S | P09871 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | HTR3A | P46098 | 1/20 | 0.45 |
| ▸ | DHODH | Q02127 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL167758 | 0.87 | ATP4A (0.54) | HPGDSCYP19A1ATP4AATP4BVCP | |
| SCHEMBL1333818 | 0.82 | L3MBTL1 (0.58) | MAPTMAPK1MEN1KMT2ANPC1 | |
| SCHEMBL14098391 | 0.80 | SMN1; SMN2 (0.61) | CYP19A1ATP4AATP4BKDM4EMAPT | |
| SCHEMBL25340620 | 0.78 | HDAC3 (0.43) | HPGDSEIF4EMEN1KMT2AECE1 | |
| SCHEMBL10924221 | 0.77 | HPGDS (0.65) | HPGDSCYP19A1ATP4AATP4BVCP | |
| SCHEMBL10809236 | 0.77 | HPGDS (0.65) | HPGDSATP4AATP4BVCPKDM4E | |
| SCHEMBL31401007 | 0.77 | MPL (0.58) | VCPEIF4ESIRT5KDM4EMAPT | |
| SCHEMBL28467752 | 0.77 | SMN1; SMN2 (0.62) | CYP19A1ATP4AATP4BEIF4EKDM4E | |
| SCHEMBL11137393 | 0.77 | HPGDS (0.64) | HPGDSATP4AATP4BVCPKDM4E | |
| SCHEMBL234658 | 0.76 | ALDH1A1 (0.63) | HPGDSCYP19A1ATP4AATP4BVCP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12065428-B2 | Anti-viral compounds | ALIGOS THERAPEUTICS, INC. (US) | 2024-08-20 | — | — | US | disclosed |
| US-20230140238-A1 | ANTI-VIRAL COMPOUNDS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2023-05-04 | — | — | US | disclosed |
| WO-2023043816-A1 | ANTI-VIRAL COMPOUNDS FOR TREATING CORONAVIRUS, PICORNAVIRUS, AND NOROVIRUS INFECTIONS | ALIGOS THERAPEUTICS, INC. (US) | 2023-03-23 | — | — | WO | disclosed |
| US-8999982-B2 | Pharmaceutically active compounds as Axl inhibitors | LEAD DISCOVERY CENTER GMBH (DE) | 2015-04-07 | — | — | US | disclosed |
| EP-2609091-B1 | PHARMACEUTICALLY ACTIVE COMPOUNDS AS AXL INHIBITORS | LEAD DISCOVERY CENTER GMBH (DE) | 2014-11-26 | — | — | EP | disclosed |
| US-20140018365-A1 | PHARMACEUTICALLY ACTIVE COMPOUNDS AS AXL INHIBITORS | MAX-PLANCK-GESELLSCHAFT ZUR FÖRDERUNG DER WISSENSCCHAFTEN E.V. (DE) | 2014-01-16 | — | — | US | disclosed |
| EP-2609091-A1 | PHARMACEUTICALLY ACTIVE COMPOUNDS AS AXL INHIBITORS | Lead Discovery Center GmbH (DE) | 2013-07-03 | — | — | EP | disclosed |
| WO-2012028332-A1 | PHARMACEUTICALLY ACTIVE COMPOUNDS AS AXL INHIBITORS | LEAD DISCOVERY CENTER GMBH (DE) | 2012-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12065428-B2 | Anti-viral compounds | EIF2AK2, ZC3HAV1, HAVCR2 | HPGDS 2011/4885CYP19A1 3784/4885ATP4A 2734/4885 |
| US-20230140238-A1 | ANTI-VIRAL COMPOUNDS | EIF2AK2, ZC3HAV1, HAVCR2 | HPGDS 2011/4885CYP19A1 3784/4885ATP4A 2734/4885 |
| US-20140018365-A1 | PHARMACEUTICALLY ACTIVE COMPOUNDS AS AXL INHIBITORS | AXL, FLT3, ERBB3 | HPGDS 1751/4885CYP19A1 3210/4885ATP4A 3711/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.